{
    "Trade/Device Name(s)": [
        "Yumizen C1200",
        "Yumizen C1200 Glucose HK",
        "Sodium Electrode",
        "Potassium Electrode",
        "Chloride Electrode"
    ],
    "Submitter Information": "HORIBA, Ltd.",
    "510(k) Number": "K183375",
    "Predicate Device Reference 510(k) Number(s)": [
        "K161837",
        "K081276"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFR",
        "JGS",
        "CEM",
        "CGZ",
        "JJE"
    ],
    "Summary Letter Date": "February 12, 2019",
    "Summary Letter Received Date": "December 6, 2018",
    "Submission Date": "November 30, 2018",
    "Regulation Number(s)": [
        "21CFR862.1345",
        "21CFR862.1665",
        "21CFR862.1600",
        "21CFR862.1170",
        "21CFR862.2160"
    ],
    "Regulation Name(s)": [
        "Glucose test system",
        "Sodium test system",
        "Potassium test system",
        "Chloride test system",
        "Discrete photometric chemistry analyzer for clinical use"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose",
        "Sodium",
        "Potassium",
        "Chloride"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Yumizen C1200 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Colorimetry",
        "Ion selective electrode (ISE)",
        "Enzymatic method (hexokinase coupled with glucose-6-phosphate dehydrogenase)",
        "Photometric measurement",
        "Potentiometry"
    ],
    "Methodologies": [
        "Endpoint assay",
        "Reaction rate assay",
        "2-point assay",
        "Constant rate assay",
        "Immunoassay",
        "Electrode method (ISE)"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Reagent",
        "Electrode"
    ],
    "Document Summary": "FDA 510(k) summary for Yumizen C1200 clinical chemistry analyzer and reagents for quantitative glucose, sodium, potassium, and chloride measurement in serum, plasma, and urine",
    "Indications for Use Summary": "Yumizen C1200 and associated reagents are intended for quantitative in vitro diagnostic measurement of glucose, sodium, potassium, and chloride in human serum, plasma, and urine for diagnosis and treatment of disorders related to carbohydrate metabolism and electrolyte imbalance in a clinical laboratory environment",
    "fda_folder": "Clinical Chemistry"
}